|
Jul 17
|
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
|
|
Jul 16
|
PureTech Announces Leadership Transition
|
|
Jun 26
|
Vor, with new CEO, changes course to target autoimmune disease
|
|
May 22
|
PureTech to Present at the Jefferies Global Healthcare Conference
|
|
May 20
|
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
|
|
Apr 23
|
PureTech Health: Notice of Results
|
|
Mar 11
|
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
|